34110834 |
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Visswanathan, R,
Hoffman, RL,
O'Doherty, I,
Kephart, SE,
Miller, N,
Huser, N,
Carelli, J,
Tseng, E,
Nagata, A,
Murray, BW,
Behenna, DC,
Freeman-Cook, KD,
Hui, A,
Ninkovic, S,
Lapek, J,
Nguyen, L,
Ornelas, MA,
Huang, B,
Sutton, SC,
Jones, R,
Zehnder, L,
Tran, K,
Boras, B,
Dann, S,
Zhang, C,
He, YA,
Ferre, RA,
Solowiej, J,
Xu, M,
Zhang, Q,
Diehl, W,
McTigue, M,
Niessen, S
|
J Med Chem |
2021 |
10973815 |
Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product
Muller, L,
Stephan, C,
Furet, P,
Fretz, H,
Zumstein-Mecker, S,
Schoepfer, J,
Soni, R,
Chaudhuri, B
|
Biochem Biophys Res Commun |
2000 |
15542782 |
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, DW,
Meade, M,
Keller, PR,
Trachet, E,
Toogood, PL,
Leopold, WR,
Pryer, NK,
Albassam, M,
Harvey, PJ,
Elliott, WL,
Zheng, X
|
Mol Cancer Ther |
2004 |
30724426 |
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
Fu, H,
Li, Y,
Wang, Y,
Lou, L,
Wang, Q,
Xie, C,
Long, F,
Bao, X,
He, Y
|
Cancer Sci |
2019 |
25486476 |
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
Bisteau, X,
Paternot, S,
Colleoni, B,
Roger, PP
|
Cell Cycle |
2014 |
26826116 |
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Tavares, FX,
Strum, JC,
Roberts, PJ,
Bisi, JE,
Sorrentino, JA
|
Mol Cancer Ther |
2016 |
17363486 |
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Sivakumar, M,
Sharma, S,
Joshi, KS,
Lal, B,
Rathos, MJ,
Joshi, RD,
Kamble, S,
Mascarenhas, M
|
Mol Cancer Ther |
2007 |
27146121 |
Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours
Smith, D,
Mann, D,
Yong, K
|
Br J Haematol |
2016 |
26606677 |
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
Brown, JR,
Kilmarx, S,
Spurgeon, SE,
Paiva, C,
Srinivasa, SP,
Soderquist, RS,
Danilov, AV,
Rowland, T,
Godbersen, JC
|
PLoS One |
2015 |
28578693 |
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Li, Z,
Yuan, J,
Wang, J,
Li, Q,
Liu, Z,
Chen, Z,
Shen, L,
Gao, J,
Lai, Y,
Wang, J
|
J Transl Med |
2017 |
27496135 |
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Bergqvist, S,
He, YA,
Lam, H,
Nagata, A,
Lee, NV,
Hu, W,
Chen, P,
Murray, BW,
Ferre, RA,
VanArsdale, T,
Solowiej, J,
Xu, M,
Yu, X,
Diehl, W
|
Mol Cancer Ther |
2016 |
28418845 |
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
Tavares, FX,
Jordan, JL,
Darr, DD,
Strum, JC,
Roberts, PJ,
Bisi, JE,
Sorrentino, JA
|
Oncotarget |
2017 |
29269870 |
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
Gillespie, KC,
Merrell, AJ,
Burns, C,
Kerwin, WS,
Deckwerth, TL,
Dixon, CP,
Dey, J,
Casalini, JR,
Grenley, MO,
Klinghoffer, RA,
Ditzler, SH,
Beirne, E,
Kleinman, EF
|
Sci Rep |
2017 |
28607489 |
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Roberts, TM,
Gygi, SP,
Geng, Y,
Polyak, K,
Sicinska, E,
Sicinski, P,
Gao, X,
Williams, JA,
Wang, H,
Yang, G,
Gerdemann, U,
Keibler, MA,
Suski, JM,
Ren, H,
Chick, JM,
Dyson, NJ,
Haining, WN,
Nicolay, BN,
Gao, H
|
Nature |
2017 |
33068248 |
Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells
Nishinaka-Arai, Y,
Nakatani, K,
Koyama, A,
Noura, M,
Adachi, S,
Kamikubo, Y,
Harata, Y,
Higashitani, M,
Matsuo, H
|
Int J Hematol |
2021 |
24919854 |
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Flack, RS,
Sanchez-Martinez, C,
Del Prado, M,
Neubauer, BL,
Lallena, MJ,
Gelbert, LM,
Chan, EM,
Iversen, P,
Lin, X,
Torres, R,
Ajamie, RT,
de Dios, A,
Kreklau, E,
Cai, S,
Cronier, D,
Young, J,
Wishart, GN
|
Invest New Drugs |
2014 |